Skin Disorders News

Patients with hereditary angioedema experienced fewer hospitalizations and ED and outpatient visits after beginning prophylactic treatment with berotralstat, according to a poster presented at a recent conference.

Arcutis Biotherapeutics reported Zoryve net sales of $21.6 million in the first quarter of 2024, the company announced in a press release.

Ruxolitinib cream 1.5% was safe and well tolerated up for the short- and long-term treatment of atopic dermatitis in adolescents, according to an analysis of two phase 3 studies.

Galderma has received filing acceptances for nemolizumab for the treatment of prurigo nodularis and atopic dermatitis in Australia, Singapore, Switzerland and the United Kingdom, the company announced in a press release.

Technoderma Medicines has dosed its first patients in its phase 2a clinical trial of topical TDM-180935 ointment for the treatment of atopic dermatitis, the company announced in a press release.

Eli Lilly and Company announced a net revenue increase of 26% in the first quarter of 2024 and the resubmission of its biologic license application for lebrikizumab for the treatment of atopic dermatitis, according to a press release.

SelectION announced positive results from its first-in-human phase 1b trial of its lead compound, a selectively-optimized peptide, for the treatment of patients with atopic dermatitis, according to a company press release.

Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.

The FDA has accepted Dermavant Science’s supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged 2 years and older, the company announced in a press release.

Dupilumab demonstrated sustained effectiveness across patientreported outcome measures in adult and pediatric individuals with atopic dermatitis, according to a study.